Startseite>>Signaling Pathways>> Metabolism>> PDE>>TMX-4100

TMX-4100

Katalog-Nr.GC63520

TMX-4100 ist ein selektiver Abbauer von Phosphodiesterase 6D (PDE6D). TMX-4100 zeigt eine hohe AbbauprÄferenz fÜr PDE6D mit DC50-Werten von weniger als 200 nM in MOLT4-, Jurkat- und MM.1S-Zellen. TMX-4100 kann fÜr die Erforschung des multiplen Myeloms verwendet werden.

Products are for research use only. Not for human use. We do not sell to patients.

TMX-4100 Chemische Struktur

Cas No.: 2367619-63-2

Größe Preis Lagerbestand Menge
5 mg
270,00 $
Auf Lager
10 mg
432,00 $
Auf Lager
25 mg
855,00 $
Auf Lager
50 mg
1.305,00 $
Auf Lager
100 mg
2.025,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC50 values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma[1].

TMX-4100 (compound 3; 1 μM; 4 h) shows a high degradation preference for PDE6D in MOLT4 cells[1].TMX-4100 has better proteome-wide degradation selectivity in MOLT4 cells, compare to PDE6D degrader FPFT-2216[1].TMX-4100 does not impede the growth of KRAS-dependent cell lines (MIA PaCa-2, NCI-H358, AGS, PA-TU-8988T cells)[1].

[1]. Teng M, et al. Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216. J Med Chem. 2022 Jan 13;65(1):747-756.

Bewertungen

Review for TMX-4100

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TMX-4100

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.